Review article

Rituximab for rheumatoid arthrits treatment: a systematic review

Lívia Lovato Pires de Lemos*a,*, Juliana de Oliveira Costa b, Marina Amaral de Ávila Machado b, Alessandra Maciel Almeida b, Mariana Michel Barbosa c, Adriana Maria Kakehast d, Vânia Eloisa de Araújo a, Augusto Afonso Guerra Júnior a, Francisco de Assis Acurcio a

*a Department of Social Pharmaceutics, Pharmacy Faculty, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
b Department of Preventive and Social Medicine, Medicine Faculty, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
c Center of Research René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, MG, Brazil
d Department of Locomotor Apparatus, Medicine Faculty, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

Article Info

Article history:
Received on 22 March 2013
Accepted on 23 August 2013

Keywords:
Rheumatoid arthritis
Rituximab
Systematic review
Safety
Efficacy

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic joint inflammation that often leads to significant disability. Several effective anti-TNF agents have been used, but some patients have shown an inadequate response. Rituximab is a therapeutic monoclonal antibody indicated in such cases.

Methods: We conducted a systematic review to access efficacy and safety of rituximab in patients with active RA which have or have not been treated with anti-TNF agents before, and to relate outcome with RF and anti-CCP serology. We searched major electronics databases, grey literature and searched for references manually. We used Review Manager®5.1 for meta-analysis.

Results: We included six RCTs comparing rituximab 1000 mg with placebo. Methotrexate was used by both groups. Treatment with rituximab was more effective in naïve and in anti-TNF treatment failure patients - ACR20/50/70 and EULAR response. We observed lower changes in Total Genant-modified Sharp score, erosion score and joint narrowing scores in the rituximab group, and SF-36, FACIT-T and HAQ-DI scores were also better in this group. There were no differences between groups regarding safety outcomes, with exception of acute injection reactions, which were more common on rituximab group. More RF/anti-CCP seropositive patients achieved ACR20 than RF/anti-CP negative patients in rituximab group.

Conclusion: Available data support the use of rituximab for the treatment of RA, as it is an effective and safe option for naïve and anti-TNF treatment failure patients. RF and anti-CCP seem to influence treatment results, but this inference needs further research.

© 2014 Sociedade Brasileira de Reumatologia. Published by Elsevier Editora Ltda. All rights reserved.
Palavras-chave:
Artrite reumatoide
Rituximabe
Revisão sistemática
Segurança
Eficácia

Introdução: A artrite reumatoide (AR) é uma doença autoimune crônica caracterizada por inflamação articular sistêmica que, com frequência, leva a significativa incapacitação. Vários agentes anti-TNF têm sido usados efetivamente, mas alguns pacientes demonstraram resposta inadequada. Rituximabe é um anticorpo monoclonal terapêutico indicado em tais casos.

Métodos: Realizou-se uma revisão sistemática para avaliar a eficácia e a segurança de rituximabe em pacientes com AR ativa previamente tratados ou não com agentes anti-TNF e para relacionar o desfecho com a sorologia para FR e anti-CCP. Pesquisaram-se importantes bancos de dados eletrônicos e a literatura não convencional, além de se fazer uma busca manual de referências. Para a meta-análise, utilizou-se o programa Review Manager® 5.1.

Resultados: Consideramos seis ERCs comparando rituximabe 1000 mg com placebo. Em ambos os grupos usou-se Metotrexato. O tratamento com rituximabe foi mais efetivo em pacientes jamais tratados e nos que não obtiveram sucesso com a terapia anti-TNF – critérios ACR 20/50/70 e EULAR. No grupo de rituximabe, observaram-se mudanças menos expressivas nos escores de Sharp/Genant, de erosão e de estreitamento do espaço articular; nesse grupo, os escores SF-36, FACIT-T e HAQ-DI também foram melhores. Não foram notadas diferenças entre grupos com relação aos desfechos de segurança, com exceção das reações agudas à infusão, que foram mais comuns no grupo de rituximabe. Ainda no grupo de rituximabe, um número maior de pacientes soropositivos para FR/anti-CCP alcançou ACR20, em comparação com pacientes negativos para RF/anti-CCP.

Conclusão: Os dados disponíveis falam em favor do uso de rituximabe para o tratamento da AR, como opção efetiva e segura para pacientes jamais tratados ou que não obtiveram sucesso com o tratamento anti-TNF. FR e anti-CCP parecem influenciar os resultados do tratamento, mas essa inferência ainda está à espera de futuras pesquisas.

© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. Todos os direitos reservados.

Introdução

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by symmetrical joint inflammation that often evolves into erosive joint damage.1-3 Its prevalence and incidence vary among countries, affecting 2% of Argentina’s population and over 10% of the U.S. population.4 In addition to the articular manifestations, which can lead to damage and functional disability, the disease is related to systemic manifestations and an increase in cardiovascular mortality.5

The development of anti-TNF monoclonal antibodies shed light on the treatment of those patients who have failed the first-line therapy, in which synthetic disease modifying drugs (DMD) such as methotrexate (MTX), sulfasalazine and leflunomide are used.6-8 However, after one year of treatment, approximately 20% of patients abandoned treatment with anti-TNF due to its ineffectiveness.9 To work around this situation, the use of a different therapeutic target is an interesting alternative.

Rituximab is a monoclonal antibody that selectively depletes peripheral CD20+ B cells. Evidence supports its use in combination with MTX in patients who have failed anti-TNF therapy and in those naïve to treatment with these agents.10-13 However, the patients’ response may be incomplete, indicating the necessity to investigate biomarkers that have predictive or prognostic value, to assist in choosing the best treatment strategy. Rheumatoid factor (RF) is an IgM antibody targeted to the constant region of IgG. The anti-cyclical citrullinated peptide (anti-CCP) antibody has more specificity for RA, relating to a more aggressive disease. Both markers are used for the diagnosis of RA and its titration corresponds to the disease activity.14

The objectives of this review were to evaluate the safety and efficacy data of rituximab, as well as to illustrate the influence of RF and anti-CCP in the outcome of treatment of patients with active RA.

Methods

This systematic review (SR) is part of a larger trial that also includes infliximab, adalimumab and etanercept, designed to evaluate the efficacy and safety of these agents in the treatment of RA. We conducted this trial according to the Cochrane handbook15 and prepared the manuscript using PRISMA Statement as reporting guidance.16

Eligibility criteria

Randomized controlled trials (RCTs) comparing a scheme with rituximab versus without rituximab in the treatment of RA in patients over 18 years of age were eligible. We excluded
trials with less than a total of 30 participants, pilot trials and dosage comparison.

**Search for trials**

We investigated the databases EMBASE (until April 2012), Cochrane Register of Controlled Trials (CENTRAL; until June 2012), MEDLINE (via PubMed; until July 2012) and LILACS (until October 2012) in order to to identify potentially eligible articles in English, Spanish or Portuguese languages. For manual search we investigated meetings’ annals (American College of Rheumatology, 2010 and 2011; European League Against Rheumatism, 2010, 2011 and 2012) dissertations and theses’ banks (OpenThesis, National Library of Australia – Trove, Biblioteca Digital Brasileira de Teses e Dissertações from USP, Theses Database of Capes, Pro Quest Dissertation & Theses Database) and reference lists of articles included in other SRs. We searched ongoing trials and unpublished trials in the databases of ClinicalTrials.gov and EUClinical Trials Register records.

**Outcome measurements**

We considered as primary outcome measures: ACR20, ACR50 and ACR70.17 The secondary outcome measures were EULAR responses,18 individual components of ACR, disease activity measured by baseline DAS28-ESR change, SF-36 scores,19,20 fatigue assessed by FACIT-F21 and adverse events (AE).

**Study selection and data extraction**

We performed the assessment of the eligibility of the trial and data collection, in a standard form, in duplicate and, when necessary, a third reviewer solved disagreements. Authors of the papers were contacted when there was any difficulty in extracting data. We organized the trials according to the previous use of DMD.

**Quality assessment and risk of bias of included trials**

We assessed the methodological quality using the modified Jadad scale22 and the risk of bias by Cochrane Collaboration tool.23 The trial was considered high risk if presented a possibility of high risk of bias in at least one of the criteria evaluated. We calculated the interobserver agreement using Kappa statistics24 using SPSS® 17 software, which we considered excellent for Jadad scale; Kappa = 0.83 ± 0.60 (SD), and substantial for assessing risk bias; Kappa = 0.71 ± 0.69. We also checked conflicts of interest declared by authors of the included articles.

**Statistical analysis**

We used the Review Manager® 5.1 software to conduct the meta-analyses using the random effects model and considered those analyses with I² > 40% and P value of chi-squared test < 0.10 with substantial heterogeneity.25 The causes of heterogeneity were investigated by the exclusion of one trial at a time and subsequent verification of the change in the values of I² and P. For dichotomous outcomes, we used the relative risk (RR) with confidence interval (CI) of 95% and standard deviation as a measure of association. Continuous outcomes were qualitatively evaluated and presented as mean ± SD. We planned subgroup analyses considering seropositivity for RF and anti-CCP and developed a sensitivity analysis using participant type for primary outcomes. We assessed meta-analyses’ publication bias by funnel chart.

**Results**

**Results of the Search**

After review by title and abstract, 249 references for rituximab, infliximab, adalimumab and etanercept were considered eligible. Six RCTs were enrolled on rituximab, comprising 15 published articles (Fig. 1).

![Fig. 1 – Flowchart of selection of trials.](image-url)
We included 15 trials in progress, and one of them was terminated prematurely in some research centres without stated justification (2008-002381-55). A trial was completed, but we could not find the publication of the results (NCT01117129). We did not include any dissertation or thesis.

**Trial characteristics**

The characteristics of RCTs included are shown in Table 1. We evaluated a total of 2,139 patients with active disease, of which 1,198 used rituximab 1,000 mg twice with an interval of 15 days. MTX was used as co-treatment for all patients. The participants averaged 50 years of age, and 80% were female. The inclusion criteria of the trials were similar in terms of the diagnostic criteria – all followed the classification criteria of the American College of Rheumatology (ACR).26

One trial evaluated outcomes in 52 and 104 weeks of MTX naïve participants who had, on average, less than one year of diagnosis.27-29 The baseline data of participants in this trial were similar to those in the other trials, with the exception of the radiographic score, much lower in those newly diagnosed patients. In the other five trials, the participants had active disease despite MTX use and averaged more than seven years of disease evolution. In two trials, the participants were naïve for anti-TNF, while the outcomes were presented for 24, 48 and 104 weeks.30-34 In the other three trials, the participants exhibited treatment failure with anti-TNF agent, while the outcomes were presented after 24 weeks of follow-up (Table 1).35-37

One trial evaluated the effectiveness of the second administration of rituximab in patients in whom the first application cycle was not sufficient to achieve remission, i.e., DAS28-ESR < 2.6.41 In this trial, all participants received rituximab in an open phase. After 24 weeks of follow-up, those patients who did not achieve remission were randomized to receive re-treatment with rituximab or placebo and were followed for another 24 weeks. We considered the results of this part of the trial in the meta-analyses.

**Assessment of methodological quality and risk of bias**

All included trials had high methodological quality (Jadad score, modified = 5). The risk of bias assessment showed that the methods of generation of allocation sequence and of ensuring allocation confidentiality were considered adequate in only one RCT.27-29 For the remaining domains, all trials had low risk of bias (Fig. 2).

**Conflicts of interest and publication bias**

All included trials were funded by the pharmaceutical industry and only one report36 did not declare a conflict of interests. The funnel plot suggested publication bias, but this analysis could not be considered robust, considering that the number of included trials was small.

**Primary outcomes**

The meta-analyses that evaluated ACR measures after 24 weeks of treatment included studies whose participants were naïve or had failed with anti-TNF treatment (n = 1,640). In general, more patients in rituximab group achieved ACR20, ACR50 and ACR70 compared to placebo. However, these analyses showed substantial heterogeneity, and the subset of patients naïve to anti-TNF displayed a robust result. But it is notewor-

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Women (%)</th>
<th>Age (years ± DP)</th>
<th>Disease duration (years ± DP)</th>
<th>Previous use of MMCD (others than MTX; no. ± DP)</th>
<th>Previous use of anti-TNF N (%) No. (DP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX virgins</td>
<td>IMAGE [29-31]</td>
<td>249</td>
<td>77</td>
<td>48,1 (12,7)</td>
<td>0,91 (1,1)</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>rituximab</td>
<td>250</td>
<td>85</td>
<td>47,9 (13,3)</td>
<td>0,92 (1,3)</td>
<td>31</td>
</tr>
<tr>
<td>Anti-TNF virgins</td>
<td>Edwards [33-36]</td>
<td>40</td>
<td>80</td>
<td>54 (11)</td>
<td>11 (7)</td>
<td>2,6 (1,3)</td>
</tr>
<tr>
<td></td>
<td>rituximab</td>
<td>40</td>
<td>75</td>
<td>54 (12)</td>
<td>12 (7)</td>
<td>2,5 (1,4)</td>
</tr>
<tr>
<td>SERENE [32]</td>
<td>placebo</td>
<td>172</td>
<td>85,5</td>
<td>52,16 (12,390)</td>
<td>7,48 (7,642)</td>
<td>1,1 (1,10)</td>
</tr>
<tr>
<td></td>
<td>rituximab</td>
<td>170</td>
<td>81,2</td>
<td>51,30 (12,644)</td>
<td>6,61 (7,294)</td>
<td>1,1 (1,11)</td>
</tr>
<tr>
<td>Failure with Anti-TNF</td>
<td>DANCER [37,38]</td>
<td>placebo</td>
<td>122</td>
<td>79,5</td>
<td>50,8 (11,7)</td>
<td>9,6 (7,7)</td>
</tr>
<tr>
<td></td>
<td>rituximab</td>
<td>122</td>
<td>76,2</td>
<td>52,1 (10,9)</td>
<td>11,3 (8,5)</td>
<td>2,5</td>
</tr>
<tr>
<td>REFLEx [39-42]</td>
<td>placebo</td>
<td>201</td>
<td>82</td>
<td>52,89 (12,31)</td>
<td>11,74 (7,68)</td>
<td>2,4 (1,8)</td>
</tr>
<tr>
<td></td>
<td>rituximab</td>
<td>298</td>
<td>81</td>
<td>52,24 (12,20)</td>
<td>12,15 (8,4)</td>
<td>2,6 (1,8)</td>
</tr>
<tr>
<td>SUNRISE [43]</td>
<td>placebo</td>
<td>157</td>
<td>79</td>
<td>54 (11)</td>
<td>11 (8,5)</td>
<td>4,1 (1,9)*</td>
</tr>
<tr>
<td></td>
<td>rituximab</td>
<td>318</td>
<td>81</td>
<td>54 (11)</td>
<td>12 (9,2)</td>
<td>4,1 (2,0)*</td>
</tr>
</tbody>
</table>

* Including anti-TNF, † 1, 2, 3 mean one, two and three agents anti-TNF, respectively.
The summarized physical component (SPC) change of SF-36 was superior and statistically significant in rituximab group compared to placebo after 24 and 52 weeks of follow-up. On the other hand, the results of the summarized mental component (SMC) change were divergent: two trials showed no difference between groups and other two showed a statistically significant difference. In joint analyses, the chances of achieving a mean change of SPC > approx. 5 and SMC > approx. 5 after 24 weeks of treatment were higher and statistically significant in participants who used rituximab. The heterogeneity of the first analysis was substantial, but the individual reports favoured rituximab (Table 2).

Secondary outcomes

In general, the group of patients who used rituximab achieved a statistically significant improvement compared to placebo in all individual components of the ACR, including in relation to the average change in HAQ-DI score. The meta-analysis of the number of participants who showed a change in HAQ-DI score ≥ 0.22 after 24 weeks from baseline (n = 1,161) pointed to the benefit of rituximab use with substantial heterogeneity, probably due to the SERENE trial. The joint analysis of two trials (n = 562) showed no statistically significant difference between groups after 48-52 weeks. After 72 weeks, there was no difference between intervention and control groups of patients with more than ten years of diagnosis. But after 104 weeks there was a difference which benefited the use of rituximab in patients with less than one year of disease progression (Table 2).

After 24 weeks of follow-up, more patients in rituximab group compared to placebo achieved good (n = 1,637) and moderate (n = 1,393) EULAR responses, but with substantial heterogeneity (data not shown). Regarding good EULAR response, in the analysis of heterogeneity (and after removal of the SERENE trial) the outcome continued favouring rituximab. The analysis of the trial that evaluated recently diagnosed patients showed that the benefit of rituximab remained after 52 and 104 weeks of follow up. The heterogeneity of good and moderate EU-LAR responses diminished with the exclusion of those participants with therapeutic failure with anti-TNF, and with the exclusion of participants naïve to anti-TNF, respectively. The change of baseline DAS28-ESR was generally higher in rituximab group compared to placebo after 24, 52 and 104 weeks of follow-up. A pooled analysis of two trials showed no difference between groups in relation to the outcomes of low activity of the disease and remission till 24 weeks of follow-up, however, more patients in rituximab group compared to placebo achieved these targets after 52 and 104 weeks in the trial that evaluated patients with less diagnosis time (Table 2).

The summarized physical component (SPC) change of SF-36 was superior and statistically significant in rituximab group compared to placebo after 24 and 52 weeks of follow-up. On the other hand, the results of the summarized mental component (SMC) change were divergent: two trials showed no difference between groups and other two showed a statistically significant difference. In joint analyses, the chances of achieving a mean change of SPC > approx. 5 and SMC ≥ approx. 5 after 24 weeks of treatment were higher and statistically significant in participants who used rituximab. The heterogeneity of the first analysis was substantial, but the individual reports favoured rituximab (Table 2).

The group using rituximab had benefits with respect to the fatigue measured by FACIT-F, as compared to placebo after 24 and 52 weeks of treatment. Likewise, the chance of achieving a clinically significant lower change after 24 weeks of treatment, i.e., a mean change in FACIT-F score ≥ approx. 3.5, was higher in participants who used the biological agent (Table 2).

Two trials reported that the participants using rituximab achieved better results in radiological outcomes than those in placebo. A joint analysis (n = 934) showed that the participants treated with the biological agent had lower probability of progression by the Sharp score (modified) compared to placebo + MTX after 104 weeks of treatment (Table 2).

Regarding safety, there was no difference between intervention and control groups regarding the incidence of severe AEs, malignancies and death. Infection was the most common AE in the trials. In any case, the rate of occurrence of serious infections was low, about 2% after 24 months of treatment in both groups, increasing to approximately 6% after this pe-
period. Acute reaction to the first infusion was more common in rituximab group compared to placebo. In the second infusion, we could observe an opposite association; more patients in placebo group exhibited a reaction. There were no deaths related to this outcome in the RCTs included (Table 2).

The loss for total follow-up was higher in placebo group compared to rituximab. Individually, the trials were different as the magnitude of the loss, ranging from 2.5% to 14% in rituximab group and from 5% to 35% in placebo group. The losses due to lack of efficacy were more frequent in placebo group and from 5% to 35% in placebo group. The distribution of patients in relation to anti-CCP was reported by a trial, with homogeneity between groups. We could also observe a smaller proportion of responders in the FR- group when compared to FR+. Anti-TNF failure

Subgroup analysis – RF and anti-CCP

With the exception of one trial that included only rheumatoid factor-positive (RF+) participants, the groups of other trials were balanced with regard to the inclusion of positive and negative participants. These latter were always minority and were not included in the overall analysis of a trial. The distribution of patients in relation to anti-CCP was reported by a trial, with homogeneity between groups.

With respect to ACR20, we could observe a smaller proportion of responders in the FR- group when compared to FR+. We could also observe that in the group FR+ the number

Fig. 3 – Forest plot depicting the statistically significant difference between rituximab and placebo in response criteria of the American College of Rheumatology (ACR) after 24 weeks of treatment. A. ACR20 (20% of improvement). B. ACR50. C. ACR70.
Table 2 – Joint analysis of the secondary outcomes of efficacy, adverse events and loss of follow-up

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Rituximab n</th>
<th>Placebo n</th>
<th>RR (95% IC)</th>
<th>P Value</th>
<th>I² (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAQ-DI &lt; 0.22</td>
<td>24 weeks [32, 36, 37, 40]</td>
<td>629</td>
<td>532</td>
<td>1.61 (1.22, 2.12)</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>48-52 weeks [29, 36]</td>
<td>288</td>
<td>274</td>
<td>1.57 (0.71, 3.44)</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>72 weeks [36]</td>
<td>40</td>
<td>40</td>
<td>4.33 (1.34, 14.05)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>104 weeks [31]</td>
<td>250</td>
<td>249</td>
<td>1.12 (1.03, 1.21)</td>
<td>-</td>
</tr>
<tr>
<td>Good EULAR response</td>
<td>24 weeks [32, 35, 37, 43]</td>
<td>946</td>
<td>619</td>
<td>3.37 (1.35, 8.43)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>52 weeks [29]</td>
<td>250</td>
<td>249</td>
<td>2.32 (1.72, 3.14)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>104 weeks [31]</td>
<td>250</td>
<td>249</td>
<td>2.10 (1.61, 2.72)</td>
<td>-</td>
</tr>
<tr>
<td>Moderate EULAR response</td>
<td>24 weeks [32, 33, 39, 43]</td>
<td>824</td>
<td>569</td>
<td>1.62 (1.10, 2.37)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Low DAS 28 activity</td>
<td>24 weeks [32, 33, 39, 43]</td>
<td>488</td>
<td>329</td>
<td>1.62 (1.10, 2.37)</td>
<td>0.0001</td>
</tr>
<tr>
<td></td>
<td>52 weeks [29]</td>
<td>250</td>
<td>249</td>
<td>2.13 (1.60, 2.84)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>104 weeks [31]</td>
<td>250</td>
<td>249</td>
<td>1.93 (1.50, 2.48)</td>
<td>-</td>
</tr>
<tr>
<td>DAS 28 remission</td>
<td>24 weeks [32, 43]</td>
<td>488</td>
<td>373</td>
<td>2.48 (1.13, 5.46)</td>
<td>0.0009</td>
</tr>
<tr>
<td></td>
<td>52 weeks [29]</td>
<td>250</td>
<td>249</td>
<td>1.21 (1.08, 1.36)</td>
<td>-</td>
</tr>
<tr>
<td>PCS (SF-36) ≥ ~5</td>
<td>24 weeks [32, 40]</td>
<td>468</td>
<td>373</td>
<td>2.48 (1.13, 5.46)</td>
<td>0.0009</td>
</tr>
<tr>
<td></td>
<td>52 weeks [29]</td>
<td>250</td>
<td>249</td>
<td>1.21 (1.08, 1.36)</td>
<td>-</td>
</tr>
<tr>
<td>MCS (SF-36) ≥ ~5</td>
<td>24 weeks [32, 40]</td>
<td>468</td>
<td>373</td>
<td>2.48 (1.13, 5.46)</td>
<td>0.0009</td>
</tr>
<tr>
<td>FACIT-F ≥ ~3.5</td>
<td>24 weeks [32, 40]</td>
<td>468</td>
<td>373</td>
<td>2.48 (1.13, 5.46)</td>
<td>0.0009</td>
</tr>
<tr>
<td>No progression at mTSS</td>
<td>24 weeks [29]</td>
<td>244</td>
<td>232</td>
<td>1.19 (1.04, 1.36)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>52 weeks [29]</td>
<td>244</td>
<td>232</td>
<td>1.19 (1.04, 1.36)</td>
<td>-</td>
</tr>
<tr>
<td>No progression at erosion score</td>
<td>24 weeks [32, 33, 37, 39, 43]</td>
<td>252</td>
<td>420</td>
<td>1.90 (1.60, 2.25)</td>
<td>0.41</td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>24 weeks [32, 33, 37, 39, 43]</td>
<td>1028</td>
<td>727</td>
<td>0.98 (0.70, 1.38)</td>
<td>0.44</td>
</tr>
<tr>
<td></td>
<td>48-52 weeks [29, 33]</td>
<td>290</td>
<td>289</td>
<td>0.93 (0.57, 1.52)</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td>104 weeks [31]</td>
<td>250</td>
<td>249</td>
<td>0.78 (0.51, 1.19)</td>
<td>-</td>
</tr>
<tr>
<td>Serious infections</td>
<td>24 weeks [32, 33, 37, 39, 43]</td>
<td>1028</td>
<td>727</td>
<td>0.98 (0.70, 1.38)</td>
<td>0.44</td>
</tr>
<tr>
<td></td>
<td>48-52 weeks [29, 33]</td>
<td>290</td>
<td>289</td>
<td>0.93 (0.57, 1.52)</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td>104 weeks [31]</td>
<td>250</td>
<td>249</td>
<td>0.78 (0.51, 1.19)</td>
<td>-</td>
</tr>
<tr>
<td>Reaction at the infusion site</td>
<td>1st infusion [29, 32, 33, 37, 39, 43]</td>
<td>1280</td>
<td>976</td>
<td>1.55 (1.30, 1.86)</td>
<td>0.42</td>
</tr>
<tr>
<td></td>
<td>2nd infusion [29, 32, 33, 37, 39, 43]</td>
<td>1238</td>
<td>936</td>
<td>0.79 (0.63, 0.99)</td>
<td>0.83</td>
</tr>
<tr>
<td>Losses of follow-up</td>
<td>24 weeks [32, 33, 37, 39, 43]</td>
<td>1030</td>
<td>727</td>
<td>0.47 (0.29, 0.76)</td>
<td>0.18</td>
</tr>
<tr>
<td></td>
<td>48-52 weeks [29, 33]</td>
<td>290</td>
<td>289</td>
<td>0.54 (0.34, 0.84)</td>
<td>0.0004</td>
</tr>
<tr>
<td></td>
<td>72 weeks [36]</td>
<td>40</td>
<td>40</td>
<td>0.48 (0.28, 0.82)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>104 weeks [31, 36]</td>
<td>290</td>
<td>289</td>
<td>0.48 (0.28, 0.82)</td>
<td>-</td>
</tr>
<tr>
<td>Losses by lack of efficacy</td>
<td>24 weeks [33, 37]</td>
<td>232</td>
<td>189</td>
<td>0.27 (0.16, 0.45)</td>
<td>0.85</td>
</tr>
<tr>
<td></td>
<td>48-52 weeks [29, 33]</td>
<td>290</td>
<td>289</td>
<td>0.19 (0.08, 0.50)</td>
<td>0.74</td>
</tr>
<tr>
<td></td>
<td>72 weeks [37]</td>
<td>40</td>
<td>40</td>
<td>0.44 (0.15, 1.33)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>104 weeks [36]</td>
<td>40</td>
<td>40</td>
<td>0.24 (0.09, 0.64)</td>
<td>-</td>
</tr>
<tr>
<td>Losses by AE</td>
<td>24 weeks [32, 33, 37, 39, 43]</td>
<td>1028</td>
<td>727</td>
<td>1.57 (0.53, 4.09)</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>48-52 weeks [29, 33]</td>
<td>290</td>
<td>289</td>
<td>0.95 (0.17, 5.34)</td>
<td>0.21</td>
</tr>
<tr>
<td></td>
<td>72 weeks [36]</td>
<td>40</td>
<td>40</td>
<td>0.33 (0.04, 3.07)</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>104 weeks [31, 36]</td>
<td>290</td>
<td>289</td>
<td>0.38 (0.17, 0.85)</td>
<td>0.67</td>
</tr>
</tbody>
</table>

AE: Adverse events, DAS 28: Disease Activity Score 28-joint assessment for swelling and tenderness, EULAR: European League Against Rheumatism, FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue, HAQ-DI: Health Assessment Questionnaire – Disability Index, MCS: Mental Component Summary, mTSS: Mean change in Genant-modified Sharp radiographic score, PCS: Physical Component Summary, SF-36: Medical Study Short-Form Health Survey.
of participants treated with rituximab achieved ACR20 that was statistically significant compared to placebo, but with substantial heterogeneity; RR = 1.71 (1.19-2.48; I² = 90%; P < 0.00001), and this was explained by the exclusion of any trial. In FR- group, there was no difference between experimental and control groups; however, the analysis also showed substantial heterogeneity; RR = 1.16 (0.73-1.85; I² = 71%, P = 0.02), with no explanation (Fig. 4).

The IMAGE trial also assessed ACR50, ACR70, good EULAR response, low activity, and remission of disease according to DAS28-ESR, percentage of participants without radiological progression and mean change in modified Sharp score in relation to seropositivity for RF and anti-CCP.27 After 52 weeks of follow-up, only the mean change in modified Sharp score was statistically different between rituximab and placebo in the analysis of participants FR+. In this trial, all participants FR- were anti-CCP-.

According to Tak et al.,28 after 104 weeks of follow-up the participants FR+ and/or anti-CCP+ in rituximab group had a higher probability of not showing radiological progression compared to placebo; odds ratio (OR, 95% CI) = 2.228 (1.513-3.281). In the analyses of the participants FR- and anti-CCP-, rituximab group showed a tendency to higher probability of non-progression compared to placebo, but without statistical significance; OD = 1.833 (0.558-6.027). Regarding ACR50, the group differences were statistically significant in the subgroup FR+ and/or anti-CCP+. The participants FR- and anti-CCP- that used placebo achieved ACR50 in greater proportion versus intervention group; however, these analyses were not statistically significant.

In SERENE trial,29 after 24 weeks of treatment (the controlled trial phase) there was no difference in relation to the change in DAS28-ESR among patients FR+ and FR- who used rituximab. In the open phase of the trial (24 to 48 weeks of treatment), the patients who had not achieved remission were re-treated with the biological agent; more patients FR+ achieved ACR50 and ACR70, compared to patients FR-.

**Discussion**

The results of efficacy and safety of this RS point to the benefit of rituximab 1000 mg applied twice at 15-day intervals associated with weekly MTX for the treatment of RA. Regarding the primary outcomes, greater number of patients achieved ACR20, ACR50 and ACR70 in rituximab group versus placebo. This result was obtained for up to 24 weeks of follow-up in patients naïve and in those patients who have failed with anti-TNF and with more than seven years of the disease; and for up to 52 weeks for patients naïve to MTX and anti-TNF and newly diagnosed. These results can also be applied to good and moderate EULAR responses.

In comparison to individual components of ACR response criteria, summarized physical and mental components of SF-36, fatigue measured by FACIT-F and in relation to the change in baseline DAS28-ESR, we noted better results with ritux-
Remission and low disease activity were reported by three trials, despite all other trials also measured disease activity by DAS28-ESR. These measures were achieved after 52 weeks of treatment for newly diagnosed patients. The prevention or minimization of the progression of joint damage is a mainstay RA treatment; however, only IMAGE and REFLEX performed an analysis of radiographic progression, and in both trials the participants who used rituximab achieved better results versus placebo after 104 weeks. We need more trials to strengthen the results of radiographic progression.

In this review we observed that the favourable results with rituximab according to ACR were more expressive in the trial that studied patients with less than one year of diagnosis, which confirms the recommendations of ACR and EULAR current guidelines, pointing to the fact that the treatment of RA will be more effective if started early.

SUNRISE was responsible for high heterogeneity in various analyses. In this trial, patients who did not achieve remission with an application of rituximab were randomized to re-treatment from 24th week. This trial showed benefits of rituximab versus placebo in all parameters measured, but the results were less significant than those shown by the other included trials. The authors reported that patients who achieved ACR20, ACR50 and ACR70 after the first application of rituximab were more likely to maintain its gains or improve with re-treatment with rituximab. On the other hand, patients who did not achieve such measures were not benefited with the second drug application.

Emery et al. conducted a joint analysis of three RCTs and its extensions – SERENE and MIRROR, with 43 participants re-treated to achieve clinical remission (Treat to Target – TT) (n = 236), and DANCER, and patients re-treated when necessary (RWN) (n = 257). The groups were homogeneous with respect to basal data, with the exception of disease duration, that was 3.6 and 8.5 years, respectively. Both groups have evolved to improve at every application of rituximab; however, patients in TT group achieved better results than participants RWN, regarding HAQ-DI and DAS-28. In addition, during the first four applications of rituximab, more patients discontinued the trial in RWN group compared to TT group, mainly due to an insufficient therapeutic response.

In general, rituximab in association with MTX proved to be as safe as MTX. Acute infusion reaction was the most common event and was more frequent in rituximab group compared to placebo, but only in the first infusion. Van Vollenhoven et al. conducted a joint analysis of six RCTs (SERENE, DANCER, REFLEX, SUNRISE, MIRROR and SIERRA), including extensions of open phase DANCER and REFLEX trials, and demonstrated that the overall incidence was 359.6 adverse events per 100 patients-year (95% CI 354.4-364.9). The AE rate was higher after the first application, falling to 329.44 events per 100 patient-years (320.59-338.53) after the second application, remaining stable until the subsequent five years of monitoring. The most common event detected was an acute infusion reaction, occurring in 25% of participants. Other AEs occurring in > 10% of the assessed population were infections, not including RA exacerbations. In this review, the mortality rate was 0.6 per 100 patient-years, and there were no deaths due to infusion reactions.

Loss of participants is critical in epidemiological trials, since the analysis, even if done by intention to treat, may be compromised. In the included RCTs, generally the losses did not exceed 20% and total loss and loss due to lack of efficacy were higher in placebo group compared to rituximab. The loss rates for EA were not different between groups.

Finckh et al. conducted a prospective cohort trial to assess which subset of patients with RA and with anti-TNF failure obtain benefit with the exchange for rituximab versus exchange for another anti-TNF agent. Blom et al. evaluated a retrospective cohort of patients who had failed with two anti-TNF agents and who were treated with a third anti-TNF drug (n = 64), or with rituximab (n = 90). These authors concluded that patients using rituximab obtained better results with respect to disease activity versus patients using anti-TNF agent. Both trials concluded that in case of failure with an anti-TNF treatment, the introduction of a biological agent with different mechanism of action, such as rituximab, would be the best conduct, increasing the efficacy of rituximab as third-line treatment.

Current guidelines from ACR for RA have established, as an alternative, the use of rituximab if the patient exhibits low activity associated with a poor prognosis, or moderate/high activity. Current guidelines from EULAR recommend the use of rituximab only after a failure with anti-TNF, despite reiterating that the approval of rituximab for use as a second line option has been discussed in Europe. The results of this trial point to a possible benefit of rituximab for patients naive to anti-TNF. However, these findings should be evaluated with caution, since we could not find any RCT to evaluate the exchange by an anti-TNF, after failure of rituximab. The possibility of use of rituximab as a second line drug and of an anti-TNF as a third drug needs to be more deeply evaluated.

Data from IMAGE, DANCER, REFLEX, and SUNRISE were used in subgroup analysis for seropositivity; we observed a trend towards greater efficacy of rituximab, compared to placebo, in the subgroup FR+ and/or anti-CCP+; however, the observed heterogeneity was high. In any case, we used the method of random effects, which may have underestimated differences between groups. The predictive value of assessment of seropositivity needs to be further explored in future clinical trials, as well as the role of other biomarkers that may be useful for deciding on the best treatment to be used for each specific type of patient.

This RS has some limitations. The possibility of selection bias could not be excluded from most trials. Moreover, all included trials were funded by pharmaceutical industry, which may have led to an overestimation of the results. Systematic reviews showed that industry-funded trials tend to show favourable results for its products, compared to not funded trials.

An inherent limitation of clinical trials, which is reflected in this RS, is the fact that they were conducted in carefully selected populations. Thus, the profile of patients does not reflect the reality, especially in relation to treatment adherence (since these patients are followed more strictly) and to comorbidities, since they exclude patients with multiple comorbidities. Depression, hypertension and diabetes, for example, negatively influence the quality of life, functionality, results and prognosis of subjects with RA.
Moreover, the analysis of which type of participant would be more benefited with the use of rituximab is not conclusive, since few trials within each group (MTX-naïve and anti-NPT-naïve) were included. In general, the efficacy analyses were heterogeneous. Nevertheless, it was possible to assess the direction of the effect that showed benefit with the use of rituximab in all outcomes assessed.

Conclusion

The trials included in this RS showed that rituximab is effective and safe compared to placebo for the treatment of RA, particularly in patients with a recent diagnosis. The effectiveness was also observed both in naïve patients to anti-TNF as in those whose treatment with these agents had failed. The use of rituximab was well tolerated by all patient subtypes. More trials are needed to evaluate the role of RF and anti-CCP antibody in predicting success in the treatment of RA with rituximab, but there is indication that RF+ and anti-CCP+ patients exhibit a better response to this biological agent.

Conflicts of Interest

Coauthor Adriana Maria Kakehasi declares conflict of interest, as she received education grant from Abbott.

REFERENCES


